2019 Predictions for Late Phase Clinical Trials: Prediction #1

Clinical Trials, Clinical Research
Chess board with hand holding king piece


2019 is here! In our latest blog series, we unpack four predictions for late phase clinical trials in 2019. First up, prediction #1: strategic as opposed to transactional R&D relationships.

Chess board with hand holding king piece

Prediction #1: Strategic as Opposed to Transactional R&D Relationships

The demarcation of “early phase” versus “late phase” clinical development is increasingly becoming archaic. Highly truncated and accelerated R&D programs coupled with a permissive regulatory environment have rendered the concept of “phase” moot across many therapeutic areas. Clinical-based CROs emerged from a strategic business model that was applicable for “overflow” business and a “feast-or-famine” business cycle. Their staffing and services were predicated on single points of contact, with a discrete request for services as an ancillary contribution.

As an interesting anecdote – in 18 years of responsibility for research and development, including full responsibility for several NDA applications, I did not request clinical CRO services once because I had no need for additional staffing and did not regard CRO contributions as particularly differentiated.

However, the radical transformation of R&D over the last decade and the rise of small, midsize, and virtual organizations has caused most sponsors to emphasize the importance of creating portfolio value by establishing integrated R&D teams with external as well as internal contributors. These teams are created at product initiation, follow the product through clinical development, and continue in support through early commercialization.

Innovative R&D companies are transforming the concept of portfolio value from one focused on product attributes to a radically different definition, which requires strategic partnering. Maximizing portfolio value by considering a wider audience of stakeholders across the continuum of research becomes a valuable exercise within discovery and development. Given the many antecedents and inflection points that vary in timing and complexity, CRO and sponsor alignment becomes a differentiator.

Worldwide Clinical Trials is the cure for the common CRO. Learn more.


You may also be interested in

Want to learn more about Worldwide Clinical Trials?